OR WAIT null SECS
© 2022 MJH Life Sciences and Psychiatric Times. All rights reserved.
© 2022 MJH Life Sciences™ and Psychiatric Times. All rights reserved.
A journal club review of “Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in phase 3 randomized clinical trial in patients with narcolepsy,” by Kushida CA, et al.
December 22nd 2021
Dr Clete Kushida discusses the results of a phase 3 clinical trial that examined once-nightly sodium oxybate in patients with narcolepsy.
January 5th 2022
Takeaways of the REST-ON clinical trial results as presented in Sleep that help clinicians learn more about the management of patients with narcolepsy.
January 12th 2022
Questions raised by a recent paper by Kushida CA, et al., highlighting symptom improvement with once-nightly sodium oxybate in patients with narcolepsy.
January 19th 2022
The potential benefits of integrating once-nightly sodium oxybate into routine clinical practice to help address treatment limitations for patients with narcolepsy.
January 26th 2022
Important next steps studying once-nightly sodium oxybate and other therapies for narcolepsy treatment.